ArticleFrontiers in oncology2022
Fertility-Sparing Treatment for Endometrial Cancer or Atypical Endometrial Hyperplasia Patients With Obesity.
Article in Frontiers in oncology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
22 citing papers in PubMed, 1 synthesis or guideline pooled it, 26 citations in OpenAlex.
- Levonorgestrel-releasing intrauterine device therapy vs oral progestin treatment for reproductive-aged patients with endometrial intraepithelial neoplasia: a systematic review and meta-analysis.Journal of the National Cancer Institute · 2024Pooled it
- Advances in the application of assisted reproductive technology in fertility preservation for female patients with malignant tumours of the reproductive systems.Annals of medicine · 2026Review
- Fat reduction mediates the efficacy of intensive lifestyle interventions on fertility-sparing treatment in overweight patients with endometrial cancer and intraepithelial neoplasia.Acta obstetricia et gynecologica Scandinavica · 2026Article
- Longitudinal study of central obesity and glucose-lipid metabolism in predicting tumor remission among fertility-sparing endometrial cancer patients.European journal of obstetrics & gynecology and reproductive biology: X · 2026Article
- Global trends in fertility-preserving treatment for endometrial cancer: a bibliometric analysis, 2005-2024.Discover oncology · 2026Article
- Management and outcomes of fertility preservation in rare Cowden syndrome-associated endometrial carcinoma: a case series.BMC women's health · 2026Article
- The Role of GLP1 Receptor Agonists and Multi-agonist Incretin Therapies for Specific Obesity-related Health Conditions: Evidence and Rationale for Prioritisation.Current obesity reports · 2026Review
- Review
- Persistent endometrial dysfunction after fertility-sparing treatment for endometrial carcinoma: insights from donor oocyte cycles.Frontiers in oncology · 2026Article
- Review
- Fertility-sparing treatment for overweight patients with early-stage endometrial cancer or atypical endometrial hyperplasia under weight loss intervention.Journal of cancer research and clinical oncology · 2025Article
- Evidence-Based Weight Management for Fertility Preservation in Endometrial Cancer Patients: Developing a Complex Intervention Based on the Medical Research Council Framework.Healthcare (Basel, Switzerland) · 2025Article
- Weight Management for Fertility-Preservation Therapy in Endometrial Cancer: Opportunities and Challenges.Current oncology reports · 2025Review
- Enhancing Progestin Therapy with a Glucagon-Like Peptide 1 Agonist for the Conservative Management of Endometrial Cancer.Cancers · 2025Article
- Integrated Identification and Immunotherapy Response Analysis of the Prognostic Signature Associated With m6A, Cuproptosis-Related, Ferroptosis-Related lncRNA in Endometrial Cancer.Cancer reports (Hoboken, N.J.) · 2024Article
- Fertility-sparing re-treatment for endometrial cancer and atypical endometrial hyperplasia patients with progestin-resistance: a retrospective analysis of 61 cases.World journal of surgical oncology · 2024Article
- Prediction of complete regression in fertility-sparing patients with endometrial cancer and apical hyperplasia: the GLOBAL model in a large Chinese cohort.Journal of translational medicine · 2024Article
- Weight-Loss and Metformin-Use Improve the Reversal Rate in Patients with Endometrial Hyperplasia.International journal of women's health · 2024Article
- Fertility-sparing surgery: a hopeful strategy for young women with cancer.Journal of medicine and life · 2023Review
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveTo evaluate the efficacy and prognosis of fertility-sparing treatment on endometrial cancer (EC) and atypical endometrial hyperplasia (AEH) patients with BMI ≥ 30 kg/m
methodsA total of 102 EC or AEH patients with obesity who received fertility-preserving therapy in the Department of Obstetrics and Gynecology, Peking Union Medical College Hospital were included in our study. All patients were followed up regularly. Clinical characteristics, treatment outcomes, adverse events, and reproductive outcomes were collected and analyzed.
resultsA total of 88 (86.3%) patients achieved complete response (CR), 92.5% in AEH and 82.3% in EC, with 6 months (3-12 months) median CR time. High remission rates were found in patients who received gonadotropin-releasing hormone agonist (GnRHa)-based regimen, were younger than 35 years old, and lost more than 10% of their weight. Fifteen (17.0%) women had developed recurrence with a median recurrence time of 26 (8-52) months. Patients who received GnRHa regimen, lost more than 10% weight, received maintenance therapy, or conceived during the follow-up period had a low probability of recurrence. Of the patients with CR, 57 women attempted to get pregnant and 16 (28.1%) patients became pregnant, 7 (12.3%) of them successfully delivered and 4 (7.0%) were in pregnancy, while 5 (8.8%) of them miscarried.
conclusionFor obese patients with EC and AEH, fertility-preserving treatment can still achieve a promising response. Weight loss of more than 10% has a positive influence on response, recurrence, as well as pregnancy rates. GnRHa could be an option for obese women due to less effect on weight gain compared to progestin therapy.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.